NYSE: MRKMerck & Co Revenue
Merck & Co revenue was $63.92B for the trailing 12 months ending Mar 31, 2025, with 657.1% growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $15.5B, down 0.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MRK annual revenue was $64.2B, with 6.7% growth year-over-year.
MRK past revenue growth
How has MRK's revenue growth performed historically?
Company
4.1%
Industry
14.97%
Market
34.96%
MRK's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
MRK's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
MRK's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance
MRK revenue history
Current Revenue
$63.9B
Current Earnings
$17.4B
Current Profit Margin
27.3%
MRK's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance
Be the first to know when MRK announces revenue.
MRK Revenue History By Year
| MRK Yearly Revenue | MRK Revenue | MRK Change | MRK Revenue Growth |
|---|---|---|---|
| 2024-12-31 | $64.17B | $4.05B | +6.74% |
| 2023-12-31 | $60.12B | $832.00M | +1.40% |
| 2022-12-31 | $59.28B | $10.58B | +21.72% |
| 2021-12-31 | $48.70B | $7.19B | +17.31% |
| 2020-12-31 | $41.52B | $2.40B | +6.13% |
| 2019-12-31 | $39.12B | -$3.17B | -7.50% |
| 2018-12-31 | $42.29B | $2.17B | +5.41% |
| 2017-12-31 | $40.12B | $315.00M | +0.79% |
| 2016-12-31 | $39.81B | $309.00M | +0.78% |
| 2015-12-31 | $39.50B | -$2.74B | -6.48% |
| 2014-12-31 | $42.24B | -$1.80B | -4.08% |
| 2013-12-31 | $44.03B | -$3.23B | -6.84% |
| 2012-12-31 | $47.27B | -$780.00M | -1.62% |
| 2011-12-31 | $48.05B | $2.06B | +4.48% |
| 2010-12-31 | $45.99B | $18.56B | +67.66% |
| 2009-12-31 | $27.43B | $3.58B | +15.00% |
| 2008-12-31 | $23.85B | -$347.70M | -1.44% |
| 2007-12-31 | $24.20B | $1.56B | +6.90% |
| 2006-12-31 | $22.64B | $624.10M | +2.84% |
| 2005-12-31 | $22.01B | -$960.90M | -4.18% |
| 2004-12-31 | $22.97B | $486.90M | +2.17% |
| 2003-12-31 | $22.49B | $1.04B | +4.85% |
| 2002-12-31 | $21.45B | $246.80M | +1.16% |
| 2001-12-31 | $21.20B | -$19.16B | -47.48% |
| 2000-12-31 | $40.36B | $7.65B | +23.38% |
| 1999-12-31 | $32.71B | $5.82B | +21.62% |
| 1998-12-31 | $26.90B | $3.26B | +13.80% |
| 1997-12-31 | $23.64B | $3.81B | +19.21% |
| 1996-12-31 | $19.83B | $3.15B | +18.87% |
| 1995-12-31 | $16.68B | $1.71B | +11.43% |
| 1994-12-31 | $14.97B | N/A | N/A |
Merck & Co Revenue FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.